In contrast, individuals with MS did not exhibit a notable increase in GFAP levels compared to age‐matched controls.[192] Overall, this microfluidic immunoassay offers enhanced clinical utility for GFAP detection in neurodegenerative diseases. This evidence concerns the gene GFAP and myeloid sarcoma.